EN DE
Watch Genomtec S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genomtec S.A. (GMT) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Genomtec S.A. stock PLN 1.34, price PLN 2.66, that is 49.6% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLGNMTC00017

GS Genomtec S.A. logo Thin data Nov 10, 2026

Genomtec S.A.

GMT · WAR
Very expensive, weak quality

Our calculation puts a fair price 50% below what the stock costs today.

Revenue last quarter +83% vs. a year ago.
Fair value 1.34 PLN · Strongly overvalued
Quality 33/100
Weak Growth (revenue 3y −19.3 %/yr in PLN)
Negative free cash flow
Trails peers (1/6)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Genomtec S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14.78 PLN 2.42 PLN Fair Value 1.34 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 2.42 PLN – 14.78 PLN · fair‑value band 1.00 PLN – 1.67 PLN · the 2.66 PLN price screens above the 1.34 PLN fair value. As of Nov 10, 2026.

Follow Genomtec in your weekly email

Every Wednesday you see whether Genomtec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland.

Show moreShow less

The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva.

It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.

Stock analysis

Genomtec S.A. (GMT) currently trades at 2.66 PLN, while our estimate is 1.34 PLN, 50% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1.00 PLN (bear) to 1.67 PLN (bull), the price of 2.66 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genomtec S.A. reported revenue of 21.0K PLN in FY2025 versus 219K PLN in FY2021, a compound −44.4%/yr. Reported net income was −10.4M PLN in FY2025.

Key figures

Market cap 45.4M PLN (≈ $11.6M) Micro · EPS (TTM) −0.5000 PLN · Return on equity −55.5% · Return on assets (EBIT) −113% (5-year average) · Operating margin −18,382% · Revenue (TTM) 35.0K PLN · Revenue growth (YoY) +83.3% · Free cash flow −11.5M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −50%, GMT screens richer than that median.

Fair Value

Bear 1.00 PLN Fair Value 1.34 PLN Bull 1.67 PLN
Price 2.66 PLN · Downside -49.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 18
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 44
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2,000.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.3%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−72,405.0% (2020) → −70,371.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GMT screens overvalued: fair value 50% below the price. Compare with Abbott Laboratories, →

Compare Genomtec S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −49.6% · Bottom 25%
Profitability
Return on assets −67.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 83.3% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.93× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs GMT
DexCom, Inc DXCM $79.92 $89.18 +12% vs GMT
Stryker Corporation SYK $324.29 $358.30 +10% vs GMT
STERIS plc STE $257.12 $279.53 +9% vs GMT
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs GMT
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs GMT
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs GMT
Abbott Laboratories, ABT $110.46 $75.28 −32% vs GMT
Medtronic plc MDT $101.59 $65.61 −35% vs GMT
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs GMT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genomtec S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genomtec S.A. Fair Value". https://www.fairvalue-calculator.com/stock/GMT

Frequently asked questions

Is Genomtec S.A. (GMT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1.34 PLN versus a price of 2.66 PLN, about 50% lower (overvalued).
What is the fair value of GMT?
Our estimate for Genomtec S.A. is 1.34 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 2.66 PLN.
What is the quality score of GMT?
Genomtec S.A. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genomtec S.A. (GMT)?
Our calculated price target is the estimate of 1.34 PLN (as of Nov 10, 2026). Cautious scenario 1.00 PLN, optimistic scenario 1.67 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Genomtec S.A. stock forecast for 2026?
Our estimate puts fair value at 1.34 PLN, about 50% lower versus a price of 2.66 PLN (overvalued). Cautious scenario 1.00 PLN, optimistic scenario 1.67 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Genomtec S.A. (GMT)?
Genomtec S.A. reported trailing-twelve-month revenue of about 35.0K PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Genomtec S.A. (GMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genomtec S.A. it is 1.34 PLN per share (as of Nov 10, 2026), against a price of 2.66 PLN.
Is Genomtec S.A. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GMT trades above its calculated fair value: price 2.66 PLN, fair value 1.34 PLN, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GMT?
No. The price is what the market pays today (2.66 PLN); the fair value is what the company's own numbers justify (1.34 PLN). For Genomtec S.A. the two are 1.32 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Genomtec S.A. worth?
The market values Genomtec S.A. at about 45.4M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 2.66 PLN; our models calculate a fair value of 1.34 PLN per share.
What do the bullish and bearish scenarios say about GMT?
Our models span a range for Genomtec S.A.: cautious scenario 1.00 PLN, base 1.34 PLN, optimistic 1.67 PLN per share (as of Nov 10, 2026, price 2.66 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genomtec S.A. (GMT)?
Balance-sheet figures for Genomtec S.A. (as of Nov 10, 2026): return on equity −55.5%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is GMT from its 52-week high?
Genomtec S.A. trades at 2.66 PLN, about 59% below its 52-week high of 6.44 PLN and 10% above the low of 2.42 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1.34 PLN is for.
Which stocks are comparable to Genomtec S.A.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genomtec S.A. stock attractive at the current price?
The data as of Nov 10, 2026: price 2.66 PLN, calculated fair value 1.34 PLN (−50%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Genomtec S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genomtec S.A. (GMT)?
The closing price on Nov 10, 2026 was 2.66 PLN. Our estimate is 1.34 PLN, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genomtec S.A. right now?
The price sits above even our optimistic bull case (1.67 PLN). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Genomtec S.A.

How large is the market capitalisation of Genomtec S.A. (GMT)?
The market capitalisation of Genomtec S.A. is 45.4M PLN (≈ $11.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Genomtec S.A. (GMT)?
Earnings per share at Genomtec S.A. are −0.5000 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Genomtec S.A. (GMT)?
The return on equity (ROE) of Genomtec S.A. is −55.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genomtec S.A. (GMT)?
On an EBIT basis the return on assets of Genomtec S.A. is −113% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genomtec S.A. (GMT)?
The operating margin of Genomtec S.A. is −18,382% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genomtec S.A. (GMT)?
Revenue at Genomtec S.A. is growing +83.3% versus a year earlier (3y avg −19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genomtec S.A. (GMT) generate?
The free cash flow of Genomtec S.A. is −11.5M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Genomtec S.A. (GMT) hold?
Genomtec S.A. holds more cash than debt, 2.9M PLN net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Genomtec S.A. in the live analysis

One click puts Genomtec S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.